×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Health Topics | Infrastructure | Money | Vaccines | BioNTech

BioNTech Says Developed Method to Detect High-Risk Variants

BioNTech
(Getty Images)

Tuesday, 11 January 2022 08:26 AM

German COVID-19 vaccine maker BioNTech said it developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with British artificial intelligence startup InstaDeep Ltd.

In a joint statement on Tuesday, BioNTech and its partner said the new computational method can analyze genetic sequencing data of new coronavirus mutations found in infected people and assesses the risk they pose within days and sometimes within just minutes.

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
German COVID-19 vaccine maker BioNTech said it developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with British artificial intelligence startup InstaDeep Ltd.
BioNTech, omicron, COVID-19, InstaDeep Ltd.
72
2022-26-11
Tuesday, 11 January 2022 08:26 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved